REVIEW ARTICLE


A Review: Medicinally Important Nitrogen Sulphur Containing Heterocycles



Praveen K. Sharma1, *, Andleeb Amin1, M. Kumar2
1 Department of Chemistry, School of of Chemical Engineering and Physical Sciences, Lovely Professional University, Phagwara, Punjab, India
2 Department of Chemistry, University of Rajasthan, Jaipur, India


© 2020 Sharma et al.

open-access license: This is an open access article distributed under the terms of the Creative Commons Attribution 4.0 International Public License (CC-BY 4.0), a copy of which is available at: https://creativecommons.org/licenses/by/4.0/legalcode. This license permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

* Address correspondence to this author at the Department of Chemistry, School of of Chemical Engineering and Physical Sciences, Lovely Professional University, Phagwara, Punjab, India; E-mail: pk_pandit1982@yahoo.com


Abstract

Nitrogen sulphur containing heterocycles have specific properties due to which they can be used as a potential material in a different type of industries such as medicinal/pharmaceutical, paint, packing and textile, required for various chemical, physical operations and their use as products. Especially dyes, paint, agrochemicals, medicine, etc. make them more significant. In present days, Nitrogen-Sulfur heterocycles are repeatedly attracting the interest of chemists due to their exceptional bioactive behavior. The present study is a review of the work carried out by a chemist in the discovery of new, effective, medicinally important heterocyclic compounds. The present review basically focused on nitrogen-sulfur heterocycles of potential therapeutic interest, especially with thiazole, thiazine, pyrimidine, morpholine and piperazine heterosystems, benzothiazines, pyrazole-benzothiazines, morpholine-benzothiazines, piperazine-benzothiazines and pyrimidine-benzothiazoles, mainly due to their unique structural features, which enable them to exhibit a number of biological and pharmacological activities. Due to a novel mode of action, a broad spectrum of activity, lesser toxicity towards mammalian cells, and suitable profiles towards humans have triggered the use of Nitrogen Sulphur containing heterocycles in designing and synthesizing their derivatives with better properties. The overall objective of the review is to discuss the importance of novel biodynamic structurally diverse heterocycles of potential therapeutic interest: pyrimidine, morpholine, piperazine, pyrozole, benothiazoles, pyrimidobenzothiazoles, 4H-1,4-benzothiazines, pyrazolyl-benzothiazines, morpholinyl-benzothiazines and piperazinylbenzothiazines in order to have access to important commercial molecules for the search of better future.

Keywords: Pyrimidobenzothiazoles, Morpholinylbenzothiazines pharmacophores, Antimicrobial, Antiviral, Benzothiazoles, Benzothiazines, Pyrazolylbenzothiazines, Piperainylbenzothiazines.



1. INTRODUCTION

Heterocycles are considered as the largest section of chemistry, especially organic chemistry. A greater part of the natural compounds produced by biotic component has heterocyclic rings as a constitutional part of their molecules. Different types of commercially important compounds alkaloids like vinblastine, reserpine, morphine, ellipticine, antibiotics like cephalosporin, penicillin etc., cardiac glycosides and different type of pesticides are heterocycles of meaning for animal and human health. The majority of the important advances have been developed by synthesizing new heterocycles which imitate natural products with similar biological activities. For that reason, scientists/researchers/chemist communities are on a nonstop search to develop better pesticides, pharmaceuticals, fungicides, compost material, weed killers, insecticides, etc. Heterocycles' role in biological system is very important. Biochemical processes of components of living organisms like RNA, DNA etc. are based on heterocycles. Except for this present life pattern and civilization, there are additional significant applications of heterocycles in the fields of cosmetics, additives, antioxidants, vulcanization accelerators dyestuffs, photographic material, reprography, data storage, solvents, and plastics. Eventually, heterocyclic chemistry is an infinite supply of exceptional compounds. A large number of models of carbon, heteroatoms and hydrogen, can be produced, which have various biological, physical and chemical properties [1-7]. The expansion of newly discovered processes and the planned use of recognized procedures for the development of heterocycles continue to strengthen the vast domain of organic chemistry.

A specific class of heterocycles having sulfur-nitrogen heteroatoms includes very important aromatic compounds that show physicochemical properties with significance in the development of futuristic materials such as magnets and molecular conductors. At present, interest has been promptly growing in accepting modifications and the characteristics of sulphur-nitrogen based heterocycles. Aromatic heterocycles containing Nitrogen (N) and sulfur(S) are resulting from aromatic carbocycles with the replacement of one or more carbon by a heteroatom in the ring. Whereas, the occurrence of sulfur and nitrogen atoms in the cyclic ring is usually related to the complexity and instability in the synthesis, however, the established nitrogen and sulfur containing heterocycles with significant properties have repeatedly been synthesized. On account of the availability of electrons (unshared pairs) and the distinction in electronegativity between carbon and heteroatoms, heterocycles are very significant in the cyclic molecular structures. Therefore, the nitrogen-sulphur heterocycles exhibit physicochemical properties and reactivity fairly diverse from the precursor carbocyclic compounds [8-12]. The sulphur-nitrogen heterocycles form a fascinating class of heterocycles and inviting the attention of the researchers due to their structural heterogeneity and biomedical properties. In view of the structural modifications with the presence of heteroatoms and the relationship of structures with the pharmacological and biological activities. In this review article, we focused on nitrogen-sulfur heterocycles of biological and pharmacological significance inculcating multi-dimensional structural features due to distinctiveness in substituents, heterocyclic systems and adjoined pharmacologically active functional groups for making them accessible for biological evaluation and SAR (structural activity relationship) studies. In this review, we have focused on nitrogen-sulfur heterocycles of potential therapeutic interest especially with thiazole, thiazine, pyrimidine, morpholine and piperazine heterosystems, benzothiazines, pyrazolylbenzothiazines, morpholinylbenzothiazines, piperazinylbenzothiazines and pyrimidobenzothiazoles, mainly due to their unique structural features, which enable them to exhibit a number of biological and pharmacological activities. The pharmacological/biological activities of heterocyclic compounds mainly depend on the structural specificity and the strength of interaction between a drug and receptors present in the biological system.

2. REVIEW OF LITERATURE

2.1. Medicinally Important Pyrimidine, Benzothiazole Fused Heterosystem: Pyrimidobenzothiazole

Pyrimidine and Thiazole nuclei are treated preferred structures as both these heterocyclic systems constitute the pharmacophore of diverse biological active molecules [13-19] Fig. (1). In medicinal chemistry, the therapeutic applications of pyrimidine derivatives are well known. RNA and DNA activities are based on nucleic acids Uracil, Thymine and cytosine, which have pyrimidine unit. Pyrimidine nucleus compounds acquire a wide variety of biological activities, like stavudine and zidovudine as antiHIV, sulphamethiazine trimethoprim, and sulphadiazine as antibacterial, idoxuridine and trifluoridine as antiviral, barbiturates e.g. phenobarbitone as sedative, 5-fluorouracil as anticancerprazosin and minoxidil as antihypertensive, hypnotics and anticonvulsant, thionzylamine as H1-antihistamine, and fervennuline and toxoflavin as antibiotics, propylthiouracil as antithyroid, sulphadoxin as antimalarial and antibacterial, etc [20]. Pyrimidine and their derivatives are very well known anti-inflammatory, analgesic and antipyretic agents [21-33].

In the same way, substituted benzothiazoles show interesting biological activities, like antiviral, anti-inflammatory, anticonvulsant, antitumor, antimicrobial and antagonists, etc [34-45]. The adjoining of one biodynamic heterocyclic system with another biodynamic heterosystem results in a molecule with structural variability and improved pharmacological activity. The fusion of heterosystems has been proven to be useful and attractive for the design of new molecular framework of therapeutically interesting drugs. With the object of discovery of exploring new heterocyclic therapeutics, we focused on pyrimidobenzothiazoles, a new class of heterocycles, incorporating two pharmacologically important heterocyclic systems, benzothiazole and pyrimidine [46-56].

Pyrimidobenzothiazoles reportedly exhibited an extensive choice of pharmacological and biological activities such as anticonvulsant [57], anti-inflammatory [58], antitumor [59], etc. Pyrimidobenzothiazoles can also act as GABA receptor binding agents [60-62].

2.2. Biodynamic Heterosystem: Benzothiazine and their Derivatives

Benzothiazines are structural analogues of phenothiazines [63-69] and exhibit similar structural flexibility along with structural specificity, fold along nitrogen and sulfur axis, as in phenothiazines. The direction of folding and the magnitude of folding angle depend to a larger extent on the position as well as the type of the other substituents on the ring system, which consequently affect the therapeutic activities considerably. The structural specificity along nitrogen-sulfur axis in phenothiazines and 4H-1,4-benzothiazines has been considered as a significant factor to be responsible for their activities and made both the series important from not only structural point of view but also from pharmacological as well as industrial view point [70-72]. The structural presentation of phenothiazine and 4H-1,4-benzothiazine ring systems according to Gordon’s model is presented to show the structural similarity of both the heterosystems Fig. (2).

Benzothiazines have also been established for their pharmacological/biological behavior such as antihypertensive [73], antiinflammatory [74], antianginal [75], antihistaminic [76], antipsychotic [77], antiemetic [78], neuroleptic [79], antibacterial [80], antioxidant properties [81], etc. 4H-1,4-Benzothiazines have also been used as colour photographic developers and dye stuffs in the industry [82-84]. Some 4H-1,4-benzothiazines along with their biopharmaceutical activities are presented in Table 1.

Fig (1). Pyrimidobenzothiazole.

Fig (2). Gordon’s model.

Table 1. Pharmacological activities of Nitrogen-Sulphur containing heterocycles.
Nitrogen-Sulphur Containing Heterocycles Activity Reference
Vasorelaxant/ KATP-Channel Openers [85]
Anti-rheumatic
Anti-proliferate
[86]
Vasorelaxant [87]
Antidiabetic [88]
KATP Channel
Openers
Vasorelaxant
[89]
Apoptosis [90]
Intercellular adhesion molecule-I (Icam-I) [91]
Intercellular adhesion molecule-I (Icam-I) [92]
Anti-inflammatory [93]
Antimalarial (Against a rodent malaria parasite Plasmodium berghei) [94]
Lipoxygenase inhibitor [95]
Antimicrobial (Antibacterial activity against Bacillus subtilis, Bacillus mega, Escherichia coli, Aspergillus arogens and antifungal activity against Aspergillus awamori) [96]
Anti-Candida [97]
Antifungal against Candida albicans [98]
Antagonistic [99]
Antibacterial against Staphylococcus aureus [100]
Antibacterial against Neisseria gonorrhoea [101]
Antimicrobial against Staphylococcus aureus, Streptococcus pneumoniae, Streptococcus pyogenes, Enterococcus faecalis and Enterococcus faecium [102]
Antimicrobial against Staphylococcus aureus, Streptococcus pneumoniae [103]
Anti-autoimmune [104]
Antitumor, anti HIV [105]
Natural pigments [106]
Antimicrobial against S. aureus [107]
Renin Inhibitor [108]
Antiviral against zika virus [109]
Anti-inflammatory [110]
Antimicrobial against staphylococci, pneumococci and enterococci [111]
Kinase Inhibitor [112]
Gaba Brian receptor [113]
Antimicrobial against Staphylococcus, Enterococcus, Streptococcus, Haemophilus, Moraxella, Escherichia, Mycobacterium, Mycoplasma, Pseudomonas, Chlamydia, Rickettsia, Klebsiella, Shigella, Salmonella, Bordetella, Clostridium, Helicobacter, Campylobacter, Legionella or Neisseria. [114]
Antibacterial [115]
Anti-obesity [116]

2.3. Pharmaceutically Important Pyrazole Derivatives: Pyrazolylbenzothiazine

Pyrazole derivatives, a set of hererocycles, occupy a significant place in pesticide and medicinal chemistry by means of a large collection of bioactivities. Pyrazole derivatives are well known and reported to show antibacterial, fungicidal, herbicidal, antimicrobial, antiinflammatory, and anticancer activities [117-127]. Pyrazophos, the fungicide was marketed by Hoechst AG in1974, which have the ability to control powdery mildew in vegetables. The significance like a novel mode of action, broad spectrum of activity, lesser toxicity towards mammalian cells, and suitable profiles towards humans have triggered the use of pyrazole in designing and synthesizing its derivatives with better properties. Recently, pyrazole compounds, like pyraclostrobin (BASF, 2001) and penthiopyrad (Mitsui Toatsu Chemicals, 1995), are found to be latent antifungal agents for the control of various plant diseases. In recent years, researchers have given considerable attention to the synthesis of pyrazole and their derivatives due to their wide ranging bioactivities obtained through modification of structural profile by a change of the substituents in pyrazole ring [128].

In view of the structural relationship with bioactivities, the synthesis of substituted 1,4-benzothiazines Fig. (3), incorporating both benzothiazine and pyrazole heterosystems with this assumption that the synthesized heterocycles will exhibit better features caused by co-existence of two types of pharmacophoric interactions with different action of mechanism have also been reported.

2.4. Medicinally Important Morpholine/Piperazine and their Derivatives: Morpholinyl/Piperazinylbenzothiazines

The systems containing morpholine fragments have attracted interest as potential biologically active compounds [129-135]. Morpholines show a wide spectrum of properties varying from medicinal field applications to agricultural use [136]. Reboxetine acts as an antidepressant drug and is applied to treat panic disorder, clinical depression, hyperactivity disorder [137]. Fenpropimorph is a broadly used leaf fungicide and is predominantly used to limit fungal diseases in cereals [138]. Trioxazine, ofloxacin, ethmosine, dextromoramide, etc. containing morpholine nucleus have also found their applications in medicine. Morpholine derivatives have been the area of interest for the pharmaceutical industry as these act as bioactive compounds and effective substrates for further elaboration. In this regard, a number of patents elucidating the biological significance of such compounds have been published [139-143]. The literature survey reveals that the compounds with morpholine Fig. (4) show enormous therapeutic uses that include antimalarial [144], antibacrerial [145], antimicrobial [146], anticonvulsant agents, antidepressant [147], lukemia [148], tranqulizer s [149] and antituberculous agents [150].

Similarly, the piperazine ring is a preferrable heterosystem in medicinal-pharmaceutical chemistry and is frequently found in the structure of various enzyme inhibitors as well as clinical therapeutics [151]. Piperazine and its derivatives act as useful synthetic building blocks and have been regularly used in the preparation of important biologically active compounds. Piperazine and its derivatives have also been shown to exhibit a wide spectrum of pharmacological and biological activities such as, antibacterial [152, 153], antineoplastic [154], antinociceptive [155], antimalarial [156], antiproleferative activity [157], Na channel blocker [158], antitumor [159], antagonistic [160], antimicrobial [161], etc.

Taking into account the significance of piperazine scaffold in a wide range of applications [162-174], we apprehended that it might be worthwhile to incorporate the piperazine heterosystem alongwith 1,4-benzothiazine Fig. (5), to synthesize therapeutically interesting heterocycles with structural diversity [175-179].

Fig (3). Pyrazolylbenzothiazine.

Fig (4). Morpholinylcarbonyl-4H-1,4-benzothiazines.

Fig (5). Piperazinylcarbonyl-4H-1,4-benzothiazines.

CONCLUSION

Literature reveals that nitrogen and sulphur containing heterosystems are truly important for the development of human and associated society. These heterosystems play an important and key role in curing process against life threating diseases, which directly influence the growth of humans and animals. The overall objective of the review is to discuss the importance of novel biodynamic structurally diverse heterocycles of potential therapeutic interest, pyrimidine, morpholine, piperazine, pyrozole, benothiazoles, pyrimidobenzothiazoles, 4H-1,4-benzothiazines, pyrazolyl-benzothiazines, morpholinyl-benzothiazines and piperazinylbenzothiazines in order to have access to important commercial molecules for the search of better future.

CONSENT FOR PUBLICATION

Not applicable.

FUNDING

None.

CONFLICT OF INTEREST

The authors declare no conflict of interest, financial or otherwise.

ACKNOWLEDGEMENTS

Declared none.

REFERENCES

[1] Katritzky AR, Rees CW. Comprehensive Heterocyclic Chemistry 1st ed. 1984.
[2] Katritzky AR, Rees CW, Scriven EFV. Comprehensive Heterocyclic Chemistry 2nd ed. 1996.
[3] Balaban AT, Oniciu DC, Katritzky AR. Aromaticity as a cornerstone of heterocyclic chemistry. Chem Rev 2004; 104(5): 2777-812.
[4] Martins MAP, Cunico W, Pereira CMP, Flores AFC, Bonacorso HG, Zanatta N. 4-Alkoxy-1,1,1- Trichloro-3-Alken-2-ones: Preparation and applications in heterocyclic synthesis. Curr Org Synth 2004; 1: 391-403.
[5] Druzhinin SV, Balenkova ES, Nenajdenko VG. Recent advances in the chemistry of α,β-unsaturated trifluoromethylketones. Tetrahedron 2007; 63: 7753-808.
[6] Ghose AK, Viswanadhan VN, Wendoloski JJ. A knowledge-based approach in designing combinatorial or medicinal chemistry libraries for drug discovery. 1. A qualitative and quantitative characterization of known drug databases. J Comb Chem 1999; 1(1): 55-68.
[7] Xu J, Stevenson J. Drug-like index: A new approach to measure drug-like compounds and their diversity. J Chem Inf Comput Sci 2000; 40(5): 1177-87.
[8] Marcos CF, Polo C, Rakitin OA, Rees CW, Torroba T. From Hunig’s Base to Bis([1,2]dithiolo)-[1,4]thiazines in One Pot: The Fast Route to Highly Sulfurated Heterocycles. Angew Chem 1997; 36: 281-3.
[9] Marcos CF, Polo C, Rakitin OA, Rees CW, Torroba T. One-pot synthesis and chemistry of bis[1,2]dithiolopyrroles. Chem Commun (Camb) 1997; 9: 879-80.
[10] Marcos CF, Rakitin OA, Rees CW, Torroba T, White AJP, Williams DJ. Tertiary amine-S2Cl2 chemistry: interception of reaction intermediates. Chem Commun (Camb) 1998; 4: 453-4.
[11] Marcos CF, Rakitin OA, Rees CW, Torroba T, White AJP, Williams DJ. Bis[1,2]dithiolo[3,4-b][4′,3′-e][1,4]thiazine-3,5-dione, a planar 1,4-thiazine. Chem Commun (Camb) 1999; 1: 29-30.
[12] García-Valverde M, Pascual R, Torroba T. Synthesis, chemistry, and dynamic NMR study of new atropisomeric 4-dialkylamino-5-chloro-1,2-dithiole-3-thiones. Org Lett 2003; 5(6): 929-32.
[13] Kappe CO. 100 years of the biginelli dihydropyrimidine synthesis. Tetrahedron 1993; 49: 6937-63.
[14] Dandia A, Khaturia S, Sarawgi P, Jain A. One-Pot Three-Component Condensation Reaction in Water: An Efficient and Improved Procedure for the Synthesis of Pyrimido[2,1-b]benzothiazoles. Phosphorous Sulphur 2007; 182: 2529-39.
[15] Varma RS. Solvent-free organic syntheses using supported reagents and microwave irradiation. Green Chem 1999; 1: 43-5.
[16] Atwal KS, Swanson BN, Unger SE, et al. Dihydropyrimidine calcium channel blockers. 3. 3-Carbamoyl-4-aryl-1,2,3,4-tetrahydro-6-methyl-5-pyrimidinecarboxylic acid esters as orally effective antihypertensive agents. J Med Chem 1991; 34(2): 806-11.
[17] Rovnyak GC, Atwal KS, Hedberg A, et al. Dihydropyrimidine calcium channel blockers. 4. Basic 3-substituted-4-aryl-1,4-dihydropyrimidine-5-carboxylic acid esters. Potent antihypertensive agents. J Med Chem 1992; 35(17): 3254-63.
[18] Khania FL, Sillinietse GO, Ozel G. Dabur.; Ozel, Ya. Ya.; Yakimenis, A. A. KhimPharm Zh 1998; 78: 1321.
[19] Cho H, Ueda M, Shima K, et al. Dihydropyrimidines: novel calcium antagonists with potent and long-lasting vasodilative and antihypertensive activity. J Med Chem 1989; 32(10): 2399-406.
[20] Belema M, Bunker A, Nguyen V, et al. PCT Int. Appl. WO 2003084, Through. Chem Abstr 2003; 139337987x
[21] Pirisino R, Bianchini F, Banchelli G, et al. Pharmacological activity of FPP028 (2-phenylpyrazolo-4-ethyl-4,7-dihydro [1,5a]pyrimidin-7-one) a new non-steroid anti-inflammatory agent. Pharmacol Res Commun 1986; 18(3): 241-56.
[22] Modica M, Santagati M, Santagati A, Cutuli V, Mangano N, Caruso A. Synthesis of new [1,3,4]thiadiazolo[3,2-a]thieno[2,3-d]pyrimidinone derivatives with antiinflammatory activity. Pharmazie 2000; 55(7): 500-2.
[23] Cenicola ML, Donnoli D, Stella L, et al. Research on heterocyclic compounds. Antiinflammatory activity of some imidazo(1,2-c)pyrimidine derivatives. Pharmacol Res 1990; 22(Suppl. 3): 80-1.
[24] Nargund LVG, Badiger VV, Yarnal SM. Synthesis and antimicrobial and anti-inflammatory activities of substituted 2-mercapto-3-(N-aryl)pyrimido[5,4-c]cinnolin-4-(3H)-ones. J Pharm Sci 1992; 81(4): 365-6.
[25] Cottam HB, Wasson DB, Shih HC, Raychaudhuri A, Di Pasquale G, Carson DA. New adenosine kinase inhibitors with oral antiinflammatory activity: synthesis and biological evaluation. J Med Chem 1993; 36(22): 3424-30.
[26] Bruni F, Costanzo A, Selleri S, et al. Synthesis and study of the anti-inflammatory properties of some pyrazolo[1,5-a]pyrimidine derivatives. J Pharm Sci 1993; 82(5): 480-6.
[27] Tozkoparan B, Ertan M, Kelicen P, Demirdamar R. Synthesis and anti-inflammatory activities of some thiazolo[3,2-a]pyrimidine derivatives. Farmaco 1999; 54(9): 588-93.
[28] Lee CH, Jiang M, Cowart M, et al. Discovery of 4-amino-5-(3-bromophenyl)-7-(6-morpholino-pyridin-3-yl)pyrido[2,3-d]pyrimidine, an orally active, non-nucleoside adenosine kinase inhibitor. J Med Chem 2001; 44(13): 2133-8.
[29] Boyle DL, Kowaluk EA, Jarvis MF, et al. Anti-inflammatory effects of ABT-702, a novel non-nucleoside adenosine kinase inhibitor, in rat adjuvant arthritis. J Pharmacol Exp Ther 2001; 296(2): 495-500.
[30] Molina P, Aller E, Lorenzo A, et al. Solid-phase synthesis and inhibitory effects of some pyrido[1,2-c]pyrimidine derivatives on leukocyte formations and experimental inflammation. J Med Chem 2001; 44(6): 1011-4.
[31] Vidal A, Ferrándiz ML, Ubeda A, Acero-Alarcon A, Sepulveda-Arques J, Alcaraz MJ. Effect of some hexahydroimidazo[1,2-c]pyrimidines in inflammatory responses involving leucocytes and macrophages. J Pharm Pharmacol 2001; 53(10): 1379-85.
[32] Bruno O, Brullo C, Ranise A, et al. Synthesis and pharmacological evaluation of 2,5-cycloamino-5H-[1]benzopyrano[4,3-d]pyrimidines endowed with in vitro antiplatelet activity. Bioorg Med Chem Lett 2001; 11(11): 1397-400.
[33] Bahekar SS, Shinde DB. Synthesis and anti-inflammatory activity of some [2-amino-6-(4-substituted aryl)-4-(4-substituted phenyl)-1,6-dihydropyrimidine-5-yl]-acetic acid derivatives. Acta Pharm 2003; 53(3): 223-9.
[34] Sawhney SN, Bhutani S. Dharamvir. Synthesis of some 2 - (2 - Benzothiazolyl) - 6 2 - (2 - Benzimidazolyl) - 6 - aryl -4,5- dihydro - 3 (211 -) pyridazinones as potential anti-flamatory agents. Indian J Chem 1987; 26B: 348-50.
[35] Singh SP, Vaid RK. Synthesis and anti-inflammatory activity of some 2-(4′-butyl-3′,5′-dimethylpyrazol-1‘yl)-6-substituted benzothiazoles and 4-butyl-1-(6’-substituted-2′-benzothiazolyl)-3-methylpyrazol-5-ones. Indian J Chem 1986; 25B: 288-91.
[36] Paramashivappa R, Phani Kumar P, Subba Rao PV, Srinivasa Rao A. Design, synthesis and biological evaluation of benzimidazole/benzothiazole and benzoxazole derivatives as cyclooxygenase inhibitors. Bioorg Med Chem Lett 2003; 13(4): 657-60.
[37] Dogruer DS, Unlu S, Sahin MF, Yesilada E. Synthesis of (2-benzothiazolone-3-yl and 2-benzothiazolone-3-yl) acetic acid derivatives and Evaluation of their Antinocioceptive and Anti-inflammatory Activity. Farmaco 1998; 53: 80.
[38] Diouf O, Depreux P, Lesieur D, Poupaert JH, Caignard DH. Synthesis and evaluation of new 2-piperazinylbenzothiazoles with high 5-HT1A and 5-HT3 affinities. Eur J Med Chem 1995; 30: 715-9.
[39] Nagarajan SR, De Crescenzo GA, Getman DP, et al. Discovery of novel benzothiazolesulfonamides as potent inhibitors of HIV-1 protease. Bioorg Med Chem 2003; 11(22): 4769-77.
[40] Jimonet P, Audiau F, Barreau M, et al. Riluzole series. Synthesis and in vivo “antiglutamate” activity of 6-substituted-2-benzothiazolamines and 3-substituted-2-imino-benzothiazolines. J Med Chem 1999; 42(15): 2828-43.
[41] Siddiqui N, Pandeya SN, Sen AP, Singh GS. A series of benzothiazolyl guanidiness were synthesized for there significant anticonvulsant actinity. Pharmak Eftiki 1992; 4: 121.
[42] Singh SP, Misra RS, Parmar SS, Brumleve SJ. Synthesis of 2-(4-arylthiosemicarbazidocarbonylthio)benzthiazoles and their monoamine oxidase inhibitory and anticonvulsant properties. J Pharm Sci 1975; 64(7): 1245-7.
[43] Ucar H, Van derpoorten K, Cacciaguerra S, et al. Synthesis and anticonvulsant activity of 2(3H)-benzoxazolone and 2(3H)-benzothiazolone derivatives. J Med Chem 1998; 41(7): 1138-45.
[44] Oketani K, Nagakura N, Harada K, Inoue T. In vitro effects of E3040, a dual inhibitor of 5-lipoxygenase and thromboxane A(2) synthetase, on eicosanoid production. Eur J Pharmacol 2001; 422(1-3): 209-16.
[45] Sreenivasa MV, Nagappa AN, Nargund LVG. Various benzothiazolotriazole derivatives possess good microbial activity. Indian J Heterocycl Chem 1998; 8: 23-7.
[46] Gopkumar P, Shivakumar B, Jayachandran E, Nagappa AN, Nargund LVG, Gurupadaiah BM. Synthesis and biological activity of 6-fluoro-7-(substituted)-(2-Np-anilino sulphonamido) benzothiazoles. Indian J Heterocycl Chem 2001; 11: 39-42.
[47] Ojha KG, Jaisinghani N, Tahiliani H. Synthesis and biological activity of N-phenyl-3-methyl-4-(benzothiazo-2′-carboxamido)-5-aryl-2-pyrazolines. J Indian Chem Soc 2002; 79: 191.
[48] Bhawsar SB, Mane DV, Sinde DB, Shingare MS, Deokate AS, Congwane LV. Synthesis of some 8-[6′-substituted-1′, 3′-benzothiazol-2′-yl) amino methyl] substituted hydroxyl coumarins and Evaluation of their antibacterial activity. Indian J Heterocycl Chem 1996; 8: 23-6.
[49] Barde AR, Barsu KH, Bobade AS. Indian Drugs 1998; 35: 554.
[50] O’Brien SE, Browne HL, Bradshaw TD, Westwell AD, Stevens MF, Laughton CA. Antitumor benzothiazoles. Frontier molecular orbital analysis predicts bioactivation of 2-(4-aminophenyl)benzothiazoles to reactive intermediates by cytochrome P4501A1. Org Biomol Chem 2003; 1(3): 493-7.
[51] Trapani V, Patel V, Leong CO, et al. DNA damage and cell cycle arrest induced by 2-(4-amino-3-methylphenyl)-5-fluorobenzothiazole (5F 203, NSC 703786) is attenuated in aryl hydrocarbon receptor deficient MCF-7 cells. Br J Cancer 2003; 88(4): 599-605.
[52] Monks A, Harris E, Hose C, Connelly J, Sausville EA. Genotoxic profiling of MCF-7 breast cancer cell line elucidates gene expression modifications underlying toxicity of the anticancer drug 2-(4-amino-3-methylphenyl)-5-fluorobenzothiazole. Mol Pharmacol 2003; 63(3): 766-72.
[53] Bradshaw TD, Trapani V, Vasselin DA, Westwell AD. The aryl hydrocarbon receptor in anticancer drug discovery: friend or foe? Curr Pharm Des 2002; 8(27): 2475-90.
[54] Bradshaw TD, Bibby MC, Double JA, et al. Preclinical evaluation of amino acid prodrugs of novel antitumor 2-(4-amino-3-methylphenyl)benzothiazoles. Mol Cancer Ther 2002; 1(4): 239-46.
[55] Shi DF, Bradshaw TD, Chua MS, Westwell AD, Stevens MFG. Antitumour benzothiazoles. Part 15: The synthesis and physico-chemical properties of 2-(4-aminophenyl)benzothiazole sulfamate salt derivatives. Bioorg Med Chem Lett 2001; 11(8): 1093-5.
[56] Hutchinson I, Chua MS, Browne HL, et al. Antitumor benzothiazoles. 14. Synthesis and in vitro biological properties of fluorinated 2-(4-aminophenyl)benzothiazoles. J Med Chem 2001; 44(9): 1446-55.
[57] Gineinah MMM. 6-, 7- And 8-(5-Aryl-1-Phenyl-2-Pyrazolin-3-ly)Imidazo- and Pyrimido[2,1-b]Benzothiazoles as Novel Antoconvulsant Agents. Sci Pharm 2001; 69(1): 53-61.
[58] Russo F, Romeo G, Santagati NA, Caruso A, Cutuli V, Amore D. Synthesis of new thienopyrimidobenzothiazoles and thienopyrimidobenzoxazoles with analgesic and antiinflammatory properties. Eur J Med Chem 1994; 29: 569-78.
[59] Zimmermann J, Bauer HH, Hohorst HJ, Voelcker G. Synthesis of 1-aldofosfamide-perhydrothiazines. Arzneimittelforschung 2000; 50(9): 843-7.
[60] Landreau C, Deniaud D, Evain M, Reliquet A, Meslin JC. Efficient regioselective synthesis of triheterocyclic compounds: imidazo[2,1-b]benzothiazoles, pyrimido[2,1-b]benzothiazolones and pyrimido[2,1-b]benzothiazoles. J Chem Soc, Perkin Trans 2002; 1: 741-5.
[61] Ai J, Wang X, Wahe H, et al. 2-Oxo-2H-Pyrimido[2,1-b]benzothiazoles inhibit brain benzodiazepine receptor binding in vitro. Pharmacology 2000; 60(4): 175-8.
[62] Trapani G, Franco M, Latrofa A, et al. Synthesis and benzodiazepine receptor binding of some imidazoand pyrimido[2,1-b]benzothiazoles. Eur J Med Chem 1996; 31: 575-87.
[63] Gupta RR. Synthetic and spectral investigation of fluorinated phenothiazines and 4H-1,4-benzothiazines as potent anticancer agents. J Fluor Chem 1993; 62: 191-200.
[64] Gupta RR, Kumar M, Gupta V. Heterocyclic Chemistry 1st ed. 1998.
[65] Gupta RR, Kumar M, Gupta V. Heterocyclic Chemistry 2nd ed. 1999.
[66] Varga JM, Kalchschmid G, Klein GF, Fritsch P. Mechanism of allergic cross-reactions-I. Multispecific binding of ligands to a mouse monoclonal anti-DNP IgE antibody. Mol Immunol 1991; 28(6): 641-54.
[67] Metwally. M.A.; El-Hossini, M.S.; El-Alblak F.Z.; Khalil, A.M. Pharmazie., Synthesis of condensed heterocycles from 3-aryl-2,4-dicarbethoxy-5-methylcyclohexanones and their testing for antimicrobial activity. 1992; 47(5): 336-9.
[68] Li H, Dryhurst G. Irreversible inhibition of mitochondrial complex I by 7-(2-aminoethyl)-3,4-dihydro-5-hydroxy-2H-1,4-benzothiazine-3-carboxyli c acid (DHBT-1): A putative nigral endotoxin of relevance to Parkinson’s disease. J Neurochem 1997; 69(4): 1530-41.
[69] Kobayashi T, Strobeck M, Schwartz A, Mori Y. Inhibitory effects of a new neuroprotective diltiazem analogue, T-477, on cloned brain Ca2+ channels expressed in Xenopus oocytes. Eur J Pharmacol 1997; 332(3): 313-20.
[70] Schreiber SL. Target-oriented and diversity-oriented organic synthesis in drug discovery. Science 2000; 287(5460): 1964-9.
[71] Teague SJ, Davis AM, Leeson PD, Oprea T. The design of leadlike combinatorial libraries. Angew Chem Int Ed Engl 1999; 38(24): 3743-8.
[72] Armstrong RW, Combs AP, Tempest PA, Brown SD, Keating TA. Multiple-component condensation strategies for combinatorial library synthesis. Acc Chem Res 1996; 29: 123-31.
[73] Cecchetti V, Schiaffella F, Tabarrini O, Fravolini A. (1,4-Benzothiazinyloxy)alkylpiperazine derivatives as potential antihypertensive agents. Bioorg Med Chem Lett 2000; 10(5): 465-8.
[74] Turk CF, Egli P, Krapcho J. Synthesis and antiinflammatory activity of the sulfoxides of 4-(3-(dimethylamino)propyl)-3,4-dihydro-2-(1-hydroxyethyl)-3-phenyl-2h -1,4-benzothiazine. J Heterocycl Chem 1977; 14: 1135-7.
[75] Kanda A, Hashimoto H. Effects of semotiadil fumarate, a novel calcium antagonist, on blood pressure and heart rate in conscious spontaneously hypertensive rats. Jpn J Pharmacol 1993; 63(1): 121-4.
[76] Sugimoto Y, Tarumi T, Zhao QE, Fujii Y, Kamei C. Effects of antiallergic drugs on histamine release from rat peritoneal mast cells induced by bradykinin. Methods Find Exp Clin Pharmacol 1998; 20(6): 457-62.
[77] King DJ, Wager E. Haematological safety of antipsychotic drugs. J Psychopharmacol (Oxford) 1998; 12(3): 283-8.
[78] Williams PI, Smith M. An assessment of prochlorperazine buccal for the prevention of nausea and vomiting during intravenous patient-controlled analgesia with morphine following abdominal hysterectomy. Eur J Anaesthesiol 1999; 16(9): 638-45.
[79] Platonov IA. [The effect of neuroleptics on blood proteins during development of toxic cerebral edema-brain swelling]. Vopr Med Khim 1995; 41(1): 27-9.
[80] Wolfe S, Zhang C, Johnston BD, Kim CK. Synthesis of the stereoisomers of a novel antibacterial agent and interpretation of their relative activities in terms of a theoretical model of the penicillin receptor. Can J Chem 1994; 72: 1066-75.
[81] Kale SB, Karale BK. Synthesis and characterization of some important indazolyl derivatives. J Heterocycl Chem 2007; 44(2): 289-301.
[82] Aiello A, Fattorusso E, Luciano P, et al. Conicaquinones A and B, two novel cytotoxic terpene quinones from the mediterranean ascidian Aplidium conicum. Eur J Org Chem 2003; 898-900.
[83] Ma Y-T, Huang M-C, Hsu F-L, Chang H-F. Thiazinedione from Xanthium strumarium. Phytochemistry 1998; 48: 1083-5.
[84] Stoodley RJ. Katritzky, A R Advances in Heterocyclic Chemistry 1st ed. 1979.
[85] Cecchetti V, Calderone V, Tabarrini O, et al. Highly potent 1,4-benzothiazine derivatives as K(ATP)-channel openers. J Med Chem 2003; 46(17): 3670-9.
[86] Matsuoka H, Ohi N, Mihara M, et al. Antirheumatic agents: Novel methotrexate derivatives bearing a benzoxazine or benzothiazine moiety. J Med Chem 1997; 40(1): 105-11.
[87] Calderone V, Spogli R, Martelli A, et al. Novel 1,4-benzothiazine derivatives as large conductance Ca2+-activated potassium channel openers. J Med Chem 2008; 51(16): 5085-92.
[88] Wang Z, Yuan Y, Chen Y, et al. Parallel solution-phase synthesis of 4H-benzo[1,4]thiazin-3-one and 1,1-dioxo-1,4-dihydro-2H-1lambda6-benzo[1,4]thiazin-3-one derivatives from 1,5-difluoro-2,4-dinitrobenzene. J Comb Chem 2007; 9(4): 652-60.
[89] Cecchetti V, Calderone V, Tabarrini O, et al. Highly potent 1,4-benzothiazine derivatives as K(ATP)-channel openers. J Med Chem 2005; 48: 6766.
[90] Marchetti C, Ulisse S, Bruscoli S, et al. Induction of apoptosis by 1,4-benzothiazine analogs in mouse thymocytes. J Pharmacol Exp Ther 2002; 300(3): 1053-62.
[91] Kaneko T, Clark RS, Ohi N, et al. Inhibitors of adhesion molecules expression; the synthesis and pharmacological properties of 10H-pyrazino[2,3-b][1,4]benzothiazine derivatives. Chem Pharm Bull (Tokyo) 2002; 50(7): 922-9.
[92] Kaneko T, Clark RS, Ohi N, et al. Piperidine carboxylic acid derivatives of 10H-pyrazino[2,3-b][1,4]benzothiazine as orally-active adhesion molecule inhibitors. Chem Pharm Bull (Tokyo) 2004; 52(6): 675-87.
[93] Chia EW, Pearce AN, Berridge MV, et al. Synthesis and anti-inflammatory structure-activity relationships of thiazine-quinoline-quinones: inhibitors of the neutrophil respiratory burst in a model of acute gouty arthritis. Bioorg Med Chem 2008; 16(21): 9432-42.
[94] Barazarte A, Camacho J, Domínguez J, et al. Synthesis, antimalarial activity, structure-activity relationship analysis of thieno-[3,2-b]benzothiazine S,S-dioxide analogs. Bioorg Med Chem 2008; 16(7): 3661-74.
[95] Bakavoli M, Nikpour M, Rahimizadeh M, Saberi MR, Sadeghian H. Design and synthesis of pyrimido[4,5-b][1,4]benzothiazine derivatives, as potent 15-lipoxygenase inhibitors. Bioorg Med Chem 2007; 15(5): 2120-6.
[96] Rathore BS, Kumar M. Synthesis of 7-chloro-5-trifluoromethyl/7-fluoro/7-trifluoromethyl-4H-1,4-benzothiazines as antimicrobial agents. Bioorg Med Chem 2006; 14(16): 5678-82.
[97] Schiaffella F, Macchiarulo A, Milanese L, Vecchiarelli A, Fringuelli R. Novel ketoconazole analogues based on the replacement of 2,4-dichlorophenyl group with 1,4-benzothiazine moiety: design, synthesis, and microbiological evaluation. Bioorg Med Chem 2006; 14(15): 5196-203.
[98] Fringuelli R, Schiaffella F, Bistoni F, Pitzurra L, Vecchiarelli A. Azole derivatives of 1,4-benzothiazine as antifungal agents. Bioorg Med Chem 1998; 6(1): 103-8.
[99] Sheibani H, Islami MR, Hassanpour A, Hosseininasab FA. Nucleophilic substitution of 2,2′-disulfanediyldianiline by β-keto esters and 1,3-diketones in the presence of triethylamine. ARKIVOC 2006; 15: 68-75.
[100] Sabatini S, Kaatz GW, Rossolini GM, Brandini D, Fravolini A. From phenothiazine to 3-phenyl-1,4-benzothiazine derivatives as inhibitors of the Staphylococcus aureus NorA multidrug efflux pump. J Med Chem 2008; 51(14): 4321-30.
[101] Miller WH, Rouse MB, Seefeld MA. Antibacterial agents. WO2006014580 A1 2006.
[102] Miller WH, Pendrak I, Seefeld MA. Antibacterial agents. WO 2006002047 A3 2006.
[103] Hubschwerlen C, Surivet JP, Acklin CZ. Beta-aminoalcohol antibiotics. WO2006099884A1 2006.
[104] Singh R, Argade A, Payan DG, et al. Methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds. WO2004014382A1 2004.
[105] Jiang L, He Y, An J. 2-mercapto-ethylamine cyclized hypocrellin and preparation process and usage thereof. CN1266061A 2002.
[106] Kaul BL, Piastra B, Wolf V. Pigments, the process of their manufacture and their use. EP 1046680A2 2000.
[107] Bur D, Hubschwerlen C, Surivet JP, Zumbrunn Acklin C. New antibiotic derivatives. WO 2006126171A2 2006.
[108] Ehara T, Hitomi Y, Konischi K, Masuya K. Substituted piperidines as renin inhibitors. WO 2006125621A1 2008.
[109] Badshah SL, Ahmad N, Ur Rehman A, et al. Molecular docking and simulation of Zika virus NS3 helicase. BMC Chem 2019; 13(1): 67-74.
[110] Denny WA, Copp BR, Pearce AN, et al. Anti-inflammatory compounds. WO 2006031134A1 2006.
[111] Pierau S, Dale G. Novel compounds having an anti-bacterial activity. WO 2006021448A1 2006.
[112] Strobel H, Nemecek C, Lesuisse D, et al. Heterocycle -substituted cyclic urea derivatives, preparation thereof and pharmaceutical use thereof as kinase inhibitors. EP 1621539A1 2006.
[113] Yuji O, Fumihiko A, Akihiko M, Satoru U, Tsuguo I. Process for the preparation of (-)-1,4-benzothiazine-2-acetic acid derivatives. WO2000076995 A1 2000.
[114] Cali P, Hjelmencrantz A, Naerum L. Peptide deformylase inhibitors. WO 2005092872 A1 20051006 2005.
[115] Molteni V, He X, He Y, Kreusch A, Nabakka J, Yang K. Bicyclic compounds and compositions as pdf inhibitors. WO 2005011611 A2 20050210 2005.
[116] Bhushan LB, Bhushan LV, Channaveerappa BA, Shivaramayya K, Rajagopalan R, Ranjan C. Bicyclic compounds, process for their preparation and pharmaceutical compositions containing them. WO9920614 A1 1999.
[117] Liu XH, Cui P, Song BA, Bhadury PS, Zhu HL, Wang SF. Synthesis, structure and antibacterial activity of novel 1-(5-substituted-3-substituted-4,5-dihydropyrazol-1-yl)ethanone oxime ester derivatives. Bioorg Med Chem 2008; 16(7): 4075-82.
[118] Tanitame A, Oyamada Y, Ofuji K, et al. Design, synthesis and structure-activity relationship studies of novel indazole analogues as DNA gyrase inhibitors with Gram-positive antibacterial activity. Bioorg Med Chem Lett 2004; 14(11): 2857-62.
[119] Velaparthi S, Brunsteiner M, Uddin R, Wan B, Franzblau SG, Petukhov PA. 5-tert-butyl-N-pyrazol-4-yl-4,5,6,7-tetrahydrobenzo[d]isoxazole-3-carboxamide derivatives as novel potent inhibitors of Mycobacterium tuberculosis pantothenate synthetase: initiating a quest for new antitubercular drugs. J Med Chem 2008; 51(7): 1999-2002.
[120] Magedov IV, Manpadi M, Slambrouck SV, et al. Discovery and investigation of antiproliferative and apoptosis-inducing properties of new heterocyclic podophyllotoxin analogues accessible by a one-step multicomponent synthesis. J Med Chem 2007; 50(21): 5183-92.
[121] Rovnyak GC, Millonig RC, Schwartz J, Shu V. Synthesis and antiinflammatory activity of hexahydrothiopyrano[4,3-c]pyrazoles and related analogues. J Med Chem 1982; 25(12): 1482-8.
[122] Wächter GA, Hartmann RW, Sergejew T, Grün GL, Ledergerber D. Tetrahydronaphthalenes: influence of heterocyclic substituents on inhibition of steroid enzymes P450 arom and P450 17. J Med Chem 1996; 39(4): 834-41.
[123] Armenise D, Trapani G, Arrivo V, Morlacchi F. Preparation of potentially bioactive aza and thiaza polycyclic compounds containing a bridgehead nitrogen atom. Synthesis of pyrrolo[1,2,3-de]-1,4-benzothiazine derivatives. J Heterocycl Chem 1990; 27: 1521-5.
[124] Vicentini CB, Mares D, Tartari A, Manfrini M, Forlani G. Synthesis of pyrazole derivatives and their evaluation as photosynthetic electron transport inhibitors. J Agric Food Chem 2004; 52(7): 1898-906.
[125] Waldrep TW, Beck JR, Lynch MP, Wright FL. Synthesis and herbicidal activity of 1-aryl-5-halo and 1-aryl-5- (trifluoromethyl)-1H-pyrazole-4-carboxamides. J Agric Food Chem 1990; 38: 541-4.
[126] Minakata S, Hamada T, Komatsu M, Tsuboi H, Kikuta H, Ohshiro Y. Synthesis and Biological Activity of 1H-Pyrrolo[2,3-b]pyridine Derivatives: Correlation between Inhibitory Activity against the Fungus Causing Rice Blast and Ionization Potential. J Agric Food Chem 1997; 45: 2345-8.
[127] Vicentini CB, Romagnoli C, Andreotti E, Mares D. Synthetic pyrazole derivatives as growth inhibitors of some phytopathogenic fungi. J Agric Food Chem 2007; 55(25): 10331-8.
[128] Li Y, Zhang HQ, Liu J, Yang XP, Liu ZJ. Stereoselective synthesis and antifungal activities of (E)-alpha-(methoxyimino)benzeneacetate derivatives containing 1,3,5-substituted pyrazole ring. J Agric Food Chem 2006; 54(10): 3636-40.
[129] Mashkovskii MD. Lekarstvennye sredstva (Drugs) 2002; 1: 253-63.
[130] a)Wijtmans R, Vink MKS, Schoemaker HE, van Delft FL, Blaauw RH, Rutjes FPJT. Biological Relevance and Synthesis of C-Substituted Morpholine Derivatives. Synthesis., 2004, 641-662. and references therein. Wilkinson, M. C. Asymmetric synthesis of an aminomethyl morpholine via double allylic substitution. Tetrahedron Lett 2005; 46: 4773.b)Lanman BA, Myers AG. Efficient, stereoselective synthesis of trans-2,5-disubstituted morpholines. Org Lett 2004; 6(6): 1045-7.
[131] Abramova TV, Bakharev PA, Vasilyeva SV, Silnikov VN. Synthesis of morpholine nucleoside triphosphates. Tetrahedron Lett 2004; 45: 4361-4.
[132] Ito K, Imahayashi Y, Kuroda T, Eno S, Saito B, Katsuki T. Palladium-catalyzed asymmetric tandem allylic substitution using chiral 2-(phosphinophenyl)pyridine ligand. Tetrahedron Lett 2004; 45: 7277-81.
[133] Clark SM, Osborn HMI. Synthetic entry to functionalised morpholines and [1,4]-oxazepanes via reductive amination reactions of carbohydrate derived dialdehydes. Tetrahedron Asymmetry 2004; 15: 3643-52.
[134] Brenner E, Baldwin RM, Tamagnan G. Asymmetric synthesis of (+)-(S,S)-reboxetine via a new (S)-2-(hydroxymethyl)morpholine preparation. Org Lett 2005; 7(5): 937-9.
[135] Abdel-Jalil RJ, Ali Shah ST, Khan KM, Voelter W. A novel route towards the synthesis of stereospecific n-substituted chiral morpholines. Lett Org Chem 2005; 2: 306-8.
[136] Pommer E-H. Chemical structure-fungicidal activity relationships in substituted morpholines. Pestic Sci 1984; 15: 285-95.
[137] Wong EHF, Sonders MS, Amara SG, et al. Reboxetine: A pharmacologically potent, selective, and specific norepinephrine reuptake inhibitor. Biol Psychiatry 2000; 47(9): 818-29.
[138] Dieckmann H, Stockmaier M, Kreuzig R, Bahadir MF. Simultaneous determination of fenpropimorph and the corresponding metabolite fenpropimorphic acid in soil. J Anal Chem 1993; 345: 784-6.
[139] Kaiho T, Kusano K, Taniyama T. Benzyl alcohol derivatives or salts thereof. WO 2005023235 A1 2005.
[140] Bridger G J, McEachern E J, Skerlj R, Schols D. Chemokine receptor binding heterocyclic compounds with enhanced efficacy. WO2004093817A2 2004.
[141] Horiuchi Y, Sone T. Jpn. Kokai Tokkyo Koho JP 2004277337 A2, Oct 7, (2004). Chem Abstr 2004; 141325708
[142] Habashita H, Kokubo M, Shibayama S, Tada H, Tanihiro T. Nitrogen-containing heterocyclic compound and pharmaceutical use thereof. WO 2004052862A1 2004.
[143] Sugihara Y, Iizawa Y, Baba M. Cyclic amine compound, process for producing the same, and use. WO 2004026833A1 2004.
[144] Singh N, Sijwali PS, Pandey KC, Rosenthal PJ. Plasmodium falciparum: Biochemical characterization of the cysteine protease falcipain-2′. Exp Parasitol 2006; 112(3): 187-92.
[145] Hirokawa Y, Kinoshita H, Tanaka T, et al. Pleuromutilin derivatives having a purine ring. Part 3: Synthesis and antibacterial activity of novel compounds possessing a piperazine ring spacer. Bioorg Med Chem Lett 2009; 19(1): 175-9.
[146] Fung HB, Kirschenbaum HL, Ojofeitimi BO. Linezolid: an oxazolidinone antimicrobial agent. Clin Ther 2001; 23(3): 356-91.
[147] Takeuchi H, Yatsugi S, Hatanaka K, et al. Pharmacological studies on YM992, a novel antidepressant with selective serotonin re-uptake inhibitory and 5-HT2A receptor antagonistic activity. Eur J Pharmacol 1997; 329(1): 27-35.
[148] a)Szulawska A, Arkusinska J, Czyz M. Accumulation of gamma-globin mRNA and induction of irreversible erythroid differentiation after treatment of CML cell line K562 with new doxorubicin derivatives. Biochem Pharmacol 2007; 73(2): 175-84.
b)Jakubowska J, Wasowska-Lukawska M, Czyz M. STI571 and morpholine derivative of doxorubicin collaborate in inhibition of K562 cell proliferation by inducing differentiation and mitochondrial pathway of apoptosis. Eur J Pharmacol 2008; 596(1-3): 41-9.
[149] Mesropyan EG, Galstyan AS, Avetisyan AA. Syntheses on the basis of 4-(Oxiran-2-ylmethyl)morpholine. Russ J Org Chem 2006; 42(12): 1845-7.
[150] Daryaee F, Kobarfard F, Khalaj A, Farnia P. Synthesis and evaluation of in vitro anti-tuberculosis activity of N-substituted glycolamides. Eur J Med Chem 2009; 44(1): 289-95.
[151] Dorsey BD, Levin RB, McDaniel SL, et al. L-735,524: the design of a potent and orally bioavailable HIV protease inhibitor. J Med Chem 1994; 37(21): 3443-51.
[152] Thomas RC, Cleek GJ, Hutchinson DK, Yamada H. Oxazolidinone antibacterial agent with tricyclic substituents. US Patent 5 1999.
[153] Davies DT, Markwell RE, Pearson ND, Takle AK. Quinoline derivatives as antibacterials. US Patent 6,911,442 2005.
[154] Erskine SG, Gwynn M, Pearson ND, Wilding EI. Compounds and methods for the treatment of neoplastic disease. US Patent 6, 803, 369 2004.
[155] Naylor A, Judd DB, Lloyd JE, Scopes DIC, Hayes AG, Birch PJ. A potent new class of kappa-receptor agonist: 4-substituted 1-(arylacetyl)-2-[(dialkylamino)methyl]piperazines. J Med Chem 1993; 36(15): 2075-83.
[156] Cunico W, Gomes CRB, Facchinetti V, et al. Synthesis, antimalarial evaluation and molecular modeling studies of hydroxyethylpiperazines, potential aspartyl protease inhibitors, part 2. Eur J Med Chem 2009; 44(9): 3816-20.
[157] Ananda Kumar CS, Benaka Prasad SB, Vinaya K, et al. Synthesis and in vitro antiproliferative activity of novel 1-benzhydrylpiperazine derivatives against human cancer cell lines. Eur J Med Chem 2009; 44(3): 1223-9.
[158] Drizin I, Gregg RJ, Scanio MJ, et al. Discovery of potent furan piperazine sodium channel blockers for treatment of neuropathic pain. Bioorg Med Chem 2008; 16(12): 6379-86.
[159] Shami PJ, Saavedra JE, Bonifant CL, et al. Antitumor activity of JS-K [O2-(2,4-dinitrophenyl) 1-[(4-ethoxycarbonyl)piperazin-1-yl]diazen-1-ium-1,2-diolate] and related O2-aryl diazeniumdiolates in vitro and in vivo. J Med Chem 2006; 49(14): 4356-66.
[160] Li JB, Xia L, Wu B, Wang T, Jiang ZZ. Design, synthesis and biological estimation of 1-(benzoxazole-2-yl)piperazine and 4-(benzoxazole-2-yl)piperidine derivatives as potential α1-AR antagonists. Chin Chem Lett 2008; 19: 1193-5.
[161] Masson M, Holappa J, Hjalmarsdottir M, Runarsson OV, Nevalainen T, Jarvinen T. Antimicrobial activity of piperazine derivatives of chitosan. Carbohydr Polym 2008; 74: 566-71.
[162] Sharma PK. Antifungal, Antibacterial and Antioxidant activities of substituted Morpholinylbenzothiazine. Der Pharmacia Lettre 2016; 8(11): 140-2.
[163] Sharma PK. Antibacterial, Antifungal and Antioxidant activities of substituted pyrazolylbenzothiazines. Der Pharmacia Lettre 2016; 8(11): 79-82.
[164] Sharma PK. Antibacterial, Antifungal and Antioxidant activities of substituted 4H-1,4-benzothiazines. Pharma Chem 2016; 8(11): 156-9.
[165] Sharma PK. Antibacterial and Antifungal activity of Piperazinylbenzothiazine. Pharma Chem 2016; 8(5): 191-3.
[166] Sharma PK. Morpholinylbenzothiazine consider as bioactive compound. Der Pharmacia Lettre 2016; 8(4): 86-90.
[167] Sharma PK. Synthesis of Bioactive substituted pyrazolylbenzothiazinones. Res Chem Intermed 2015; 41(9): 6141-8.
[168] Sharma PK. Synthesis and Antimicrobial Activity of Morpholinyl/Piperazinylbenzothiazines. Med Chem Res 2012; 21(8): 2072-8.
[169] Sharma PK. Synthesis and Antimicrobial activity of Structurally flexible Heterocycles with the 1,4-Thiazine Heterosystem. Res Chem Intermed 2011; 37(8): 1103-11.
[170] Sharma PK. Synthesis and Antimicrobial activity of 2H-pyrimido [2,1-b]benzothiazol-2-ones. Res Chem Intermed 2010; 36(8): 985-93.
[171] Sharma PK. One-pot, Multicomponent Sequential Synthesis of Benzothiazoloquinazolinones. Synth Commun 2010; 40(16): 2347-52.
[172] Sharma PK. N-bridged bioactive heterocycles: Synthesis of 2-methyl-4H-pyrimido [2, 1-b] benzothiazol-4-ones. Res Chem Intermed 2009; 35: 35-41.
[173] Sharma PK. Regioselective one-pot synthesis of 5-chloro-3-methyl-8-trifluoromethyl-4H-1,4-benzothiazines. Heterocycl Commun 2019; 15(2): 127-33.
[174] Sharma PK. Synthesis of 2,4-diaryl-2, 3-dihydro-1, 5-benzothiazepines. Heterocycl Commun 2008; 14(3): 155-60.
[175] Sharma PK. Synthesis, spectral, energetic and reactivity properties of phenothiazines: Experimental and computational approach. J Chem Pharm Res 2015; 7(11): 462-73.
[176] Chattopadhyay SK. Recent advancement in the synthesis of 1,2- and 2,1-benzothiazines. Synth Commun 2018; 48(24): 3033-78.
[177] Makhova NN. Progress in the chemistry of nitrogen-, oxygen- and sulfur-containing heterocyclic systems. Russ Chem Rev 2020; 89(1): 55.
[178] Pathania S, Narang RK, Rawal RK. Role of sulphur-heterocycles in medicinal chemistry: An update. Eur J Med Chem 2019; 180: 486-508.
[179] Jampilek J. Heterocycles in Medicinal Chemistry. Molecules 2019; 24(21): 3839.